[4] Organovo also partners with biopharmaceutical companies and academic medical centers to design, build, and validate more predictive in vitro tissues for disease modeling and toxicology.

Organovo is actively developing its technology with the intention of eventually being able to replicate entire human organs for transplant.

[6] In 2015, Organovo signed an agreement to provide processes and technology to produce 3D printed human skin to L'Oreal for use in testing the safety and efficacy of cosmetic products.

[8] Organovo went public on OTC markets in 2012 via a reverse merger with shell company Real Estate Restoration and Rental, Inc.

He discussed how bioprinting may solve problems that pertain to organ shortages and high medical costs.